Michael Morris, MD, of Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the CONDOR study (NCT03739684) which aims to evaluate the diagnostic performance and safety of 18F-DCFPyL (PyL) PET/CT imaging in patients with suspected recurrence of prostate cancer who have negative or equivocal findings on conventional imaging. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
